Citigroup downgraded Galapagos NV from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/22/2025 | $40.00 | Market Perform → Outperform | Leerink Partners |
| 8/5/2025 | Hold → Sell | Deutsche Bank | |
| 2/14/2025 | $31.00 → $22.00 | Equal-Weight → Underweight | Morgan Stanley |
| 11/20/2024 | Hold → Reduce | Kepler | |
| 9/9/2024 | $24.00 | Market Perform | Leerink Partners |
| 8/2/2024 | Outperform → Mkt Perform | Raymond James | |
| 3/28/2024 | $41.00 → $31.00 | Neutral → Underperform | BofA Securities |
| 3/7/2024 | $38.00 | Equal-Weight | Morgan Stanley |
Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company's cell therapy activities. On October 21, 2025, Galapagos announced its intention to wind down its cell therapy activities following a comprehensive strategic review and sale process, including an exploration of potential divestment options. This decision was subject to the conclusion of consultations with works councils in Belgium and the Netherlands, which have now been completed. "We have now co
GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical significance in primary endpoint analysis The safety profile was consistent with previous studies with GLPG3667 Galapagos will evaluate all strategic alternatives, including resumption of its partnering process, to accelerate further development of GLPG3667 in dermatomyositis and potentially other severe auto-immune indic
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy candidate, GLPG5101, during an oral presentation (#662) at the 67th American Society of Hematology (ASH) Annual Meeting. "The new and updated results from the Phase 2 ATALANTA-1 study demonstrate that GLPG5101 offers timely treatment with low rates of high-grade toxic
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
S-8 - GALAPAGOS NV (0001421876) (Filer)
Leerink Partners upgraded Galapagos NV from Market Perform to Outperform and set a new price target of $40.00
Deutsche Bank downgraded Galapagos NV from Hold to Sell
Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously
New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board's composition with the Company's strategic direction and support its focus on transformational business development to build a pipeline of novel medicines in areas of high unmet medical need. Seasoned biopharma executive Dr. Neil Johnston has been appointed to the Board of Directors by way of co-
Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025. Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period. "We are very pleased to welcome Fred to the executive team," said Henry Gosebruch, CEO of Galapagos. "He brings a unique combination of top-tier legal expertise, global business transaction experience, and deep strategic understanding of the biopharma ecosystem. His proven track record of negotiating complex, high-impact partnerships and acquisitions, and fostering cross-f
Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening the Company's leadership team. They will both report to Henry Gosebruch, CEO, and join the Company's Management Committee. "We are excited to welcome Sooin and Dan to our senior leadership," said
Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company's cell therapy activities. On October 21, 2025, Galapagos announced its intention to wind down its cell therapy activities following a comprehensive strategic review and sale process, including an exploration of potential divestment options. This decision was subject to the conclusion of consultations with works councils in Belgium and the Netherlands, which have now been completed. "We have now co
Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion Management to host a conference call tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET Mechelen, Belgium; November 5, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced its financial results for the first nine m
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -
SC 13G/A - GALAPAGOS NV (0001421876) (Subject)
SC 13D/A - GALAPAGOS NV (0001421876) (Subject)
SC 13D - GALAPAGOS NV (0001421876) (Subject)